Novavax, Inc. (NASDAQ:NVAX) shares traded -2.28% lower at $4.72 on Wall Street last session.
NVAX stock price is now 3.01% away from the 50-day moving average and -26.59% away from the 200-day moving average. The market capitalization of the company currently stands at $660.56M.
With the price target maintained at $15, B. Riley Securities recently Upgraded its rating from Neutral to Buy for Novavax, Inc. (NASDAQ: NVAX). On April 20, 2023, TD Cowen Downgraded its previous ‘Outperform’ rating to ‘Market Perform’ on the stock reducing its target price from $55 to quote $10, while ‘B. Riley Securities’ rates the stock as ‘Neutral’
A total of 5.82% of the company’s stock is owned by insiders.
During the past 12 months, Novavax, Inc. has had a low of $3.53 and a high of $11.36. The fifty day moving average price for NVAX is $4.5804 and a two-hundred day moving average price translates $6.4143 for the stock.
The latest earnings results from Novavax, Inc. (NASDAQ: NVAX) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$1.44, missing analysts’ expectations of -$0.45 by -0.99. This compares to -$2.25 EPS in the same period last year. The company reported revenue of $291.34 million for the quarter, compared to $357.4 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -18.48 percent. For the current quarter, analysts expect NVAX to generate $101.45M in revenue.
Novavax, Inc.(NVAX) Company Profile
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
